CYTOMEGALOVIRUS INFECTION AND GRAFT REJECTION IN RENAL TRANSPLANTATION
- 1 March 2001
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 71 (6), 764-767
- https://doi.org/10.1097/00007890-200103270-00013
Abstract
Cytomegalovirus (CMV) infection and CMV disease have been associated with acute and chronic graft rejection. The introduction of the sensitive CMV antigenemia pp65 assay for detection of CMV infection allowed us to study the time course of CMV infection and acute rejection and the long-term outcome in renal transplant recipients with and without a CMV risk constellation. Prospective single center study including 48 renal transplant recipients at risk for CMV infection (donor and/or recipient CMV seropositive) and a control group of 36 CMV seronegative recipients of CMV seronegative kidney donors. Evidence of CMV infection was monitored by the CMV antigenemia pp65 assay every 1 to 2 weeks and compared with the occurrence of acute rejection in the posttransplant period and graft function at 5 years. CMV infection developed in 83% (40/48) of patients of the CMV risk group within 4 months posttransplant. A total of 18 of patients experienced an acute rejection episode (control group 16/36;P =0.65). In 12/18 CMV infection followed rejection and in three patients antigenemia preceded the diagnosis of rejection. In three patients CMV antigenemia remained negative. Five-year follow up: Patient survival (44/48 vs. 31/36;P =0.48), graft survival (38/48 vs. 27/36;P =0.79), number of patients with at least one acute rejection episode: CMV risk group: 42.1%, control group 51% (P =0.46), serum creatinine: CMV risk group:130±66 μmol/liter, control group: 126±37 μmol/liter (P =0.56), proteinuria: CMV risk group: 0.02±0.02 g/mmol creatinine, control group: 0.02±0.02 g/mmol creatinine (P =1.0). CMV infection within 4 months posttransplant, as defined by a positive antigenemia assay was not found to be a risk factor for acute graft rejection or chronic graft dysfunction at 5 years.Keywords
This publication has 16 references indexed in Scilit:
- Cytomegalovirus (CMV)–Specific T Cell Immunity after Renal Transplantation Mediates Protection from CMV Disease by Limiting the Systemic Virus LoadThe Journal of Infectious Diseases, 1999
- Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal TransplantationNew England Journal of Medicine, 1999
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- CYTOMEGALOVIRUS PROPHYLAXIS WITH ANTIVIRAL AGENTS IN SOLID ORGAN TRANSPLANTATIONTransplantation, 1998
- EFFECT OF CYTOMEGALOVIRUS ON AN EXPERIMENTAL MODEL OF CHRONIC RENAL ALLOGRAFT REJECTION UNDER TRIPLE-DRUG TREATMENT IN THE RAT1Transplantation, 1997
- LONG-TERM PROGNOSIS OF RENAL TRANSPLANTATION AFTER PREEMPTIVE TREATMENT OF CYTOMEGALOVIRUS INFECTIONTransplantation, 1997
- CYTOMEGALOVIRUS ANTIBODY STATUS AND RENAL TRANSPLANTATION: 1987-1994Transplantation, 1996
- A RANDOMIZED PROSPECTIVE TRIAL OF PROPHYLACTIC IMMUNOSUPPRESSION WITH ATG-FRESENIUS VERSUS OKT3 AFTER RENAL TRANSPLANTATIONTransplantation, 1995
- Late-acute renal allograft rejection and symptomless cytomegalovirus infectionThe Lancet, 1994
- CYTOMEGALOVIRUS INFECTION—AN ETIOLOGICAL FACTOR FOR REJECTION? A PROSPECTIVE STUDY IN 242 RENAL TRANSPLANT PATIENTSTransplantation, 1993